Bits in Bio Discussion: Genomics, Dx, and Data

Genomics is moving from a diagnostic endpoint to a growing data layer for biology. Join for a conversation on how genomic diagnostics, data infrastructure, and AI are beginning to shape the next generation of bio. Speakers include: Mimi Lee: Former ARPA-H PM, physician-scientist, visionary thinker, artist, and healer committed to serving patients patient to serving patients. Philip Fradkin - Co-Founder @ Blank Bio (YC S25) Sophie Liu - Senior Director of Business Development @ Complete Genomics Jessime Kirk - Co-Founder @ BIOS Genomics Sponsors: Bits in Bio connects the bioeconomy. We bring together innovators working at the intersection of software, AI, and biology. Our global community of over 12,000 members includes leading VCs, founders, and scientists. Benchling is the leading AI platform for biotech R&D, unifying scientific data and automating workflows to accelerate discovery and development. Trusted by more than 1,300 companies worldwide, from pioneering startups to global leaders like Merck, Moderna, and Sanofi, Benchling gives scientists a single place to capture, connect, and act on data across the entire R&D lifecycle. With Benchling AI, agents and models work directly inside scientific workflows, grounded in structured data. The result is faster teams, better molecules, and breakthroughs that reach the world sooner. AtlasBase is pioneering Molecular Computing, bridging the gap between IT and biotechnology. The company is redefining global infrastructure by driving breakthroughs across both Molecular Compute and Molecular Data Storage. By commercializing synthetic DNA-based technology, AtlasBase delivers ultra-high-density, low-maintenance, and carbon-conscious solutions built for the explosive growth of world data. Leveraging nature’s most durable medium, AtlasBase provides a virtually permanent foundation that transforms how the world processes and secures its most critical information. MyOme is a genome-first genetic testing company focused on proactive risk analysis and rare disease diagnostics.